Optimal stroke prevention in patients with patent foramen ovale

Affiliations

Comment

Bernhard Meier. Lancet Neurol. 2018 Dec.

. 2018 Dec;17(12):1027-1028.

doi: 10.1016/S1474-4422(18)30369-7. Epub 2018 Oct 16.

¹ Department of Cardiology, University Hospital, 3010 Bern, Switzerland. Electronic address: bernhard.meier@insel.ch.

No abstract available

Comment in

Optimal stroke prevention in patients with PFO.
Melis M, Ricci S, Toni D; editorial committee of the Italian National Guidelines on Stroke. Melis M, et al. Lancet Neurol. 2019 Mar;18(3):231. doi: 10.1016/S1474-4422(19)30017-1. Epub 2019 Feb 12. Lancet Neurol. 2019. PMID: 30784551 No abstract available.

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Messé SR, Spence JD, Nedeltechev K, Perera K, Santo G, Olavarria V, Lindgren A, Bangdiwala S, Shoamanesh A, Berkowitz SD, Mundl H, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators. Kasner SE, et al. Lancet Neurol. 2018 Dec;17(12):1053-1060. doi: 10.1016/S1474-4422(18)30319-3. Epub 2018 Sep 28. Lancet Neurol. 2018. PMID: 30274772 Free PMC article. Clinical Trial.